Date:	6/19/2024
Your Name:	Matthew Anderson
Manuscript Title:	[Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea [⊠]	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Much (A)

Date:	9/20/2023
Your Name:	Andreas Jeromin
Manuscript Title:	Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals
Manuscript Number (if known):	ADJ-D-23-01032

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as neede	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial plann	ng of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	[⊠] None	Click the tab key to add additional rows.
		Time frame: past 36 mg	nths
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	ALZpath, Inc.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	ALZpath, Inc.	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	Employee of ALZpath, Inc.	
	Please place an "X" next to the following statement to indicate your agreement:		
Plea [⊠]			

Date:	6/19/2024
Your Name:	J. Wesson Ashford, MD, PhD
Manuscript Title:	[Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	[⊠] None	Click the tab key to add additional rows.
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	Unpaid consultant to MemTrax, LLC	
Plea	Please place an "X" next to the following statement to indicate your agreement:		
	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	19th June 2024
Your Name:	Sasha Bozeat
Manuscript Title:	Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial planning of the work		of the work	
All support for the present manuscript (e.g., funding, provision		X	None	
	of study materials, medical writing,			Click the tab key to add additional rows.
	article processing			Citck the tab key to add additional rows.
	charges, etc.) No time limit for			
	this item.			
			Time frame: past 36 month	s
2	Grants or contracts from any entity (if not	x	None	
	indicated in item #1 above).			
	"I doove,			
3	Royalties or licenses	х	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)	
4	Consulting fees	x None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	x None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	x None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	χ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	x None	
11	Stock or stock options	x None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	x None	
13	Other financial or non-financial interests	□ None I am an employee of Hoffman-La Roche and I own stock options of that company	
Plea:	Please place an "X" next to the following statement to indicate your agreement: X I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	6/25/2024
Your Name:	Samantha C. Burnham
Manuscript Title:	[Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	[⊠] None	Click the tab key to add additional rows.
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	CSIRO: METHOD FOR DETECTION OF A NEUROLOGICAL DISEASE Publication number: 20140086836	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	□ None Eli Lilly	Stock holder
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	Eli Lilly	Employee
Plea [⊠]	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	Click or tap to enter a date.
Your Name:]	Dr Chinedu Udeh-Momoh
Manuscript Title:	[Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	[⊠] None	Click the tab key to add additional rows.
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	None 2024 - MRC UKRI Applied Global Health award 2023 - Wellcome Leap Dynamic Resilience grant award 2023 - Alzheimer's Association Sex and Gender Differences Award 2023 - Davos Alzheimer's Collaborative Global Cohort Fund 2023 - Global Brain Health Institute Project Award 2022 - UK Defence and Security Accelerator, Veterans' Health Innovation Fund 2022 - RoseTrees Foundation Seedcorn award	Payment made to institution Payment made to institution Payment made to institution Payment made to institution Payment made to institution Payment made to institution Payment made to institution Payment made to institution

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
æ	Royalties or licenses	None None	
4	Consulting fees	Braina nd Mind Institute, Aga Khan University, Kenya	Payment made to me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	Dementia and Brain Aging in LMIC 2022 conference – Alzheimer's Association Competitive Travel Fellowship for oral presentation at the LMIC meeting in Nairobi, Kenya. Alzheimer's Association International conference (AAIC) 20222 – Alzheimer's Association Competitive Travel Fellowship for oral presentation at the AAIC meeting in San Diego, USA.	Payment made to me Payment made to me
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Elected Trustee at British Society for Neuroendocrinology (roles: EDI Chair and Grants Committee member) Executive Committee member, Alzheimer's Association ISTAART Expert Committee member, NIH-Funded National Academies of Science, Engineering and Medicine (NASEM) project to determine research priorities for ADRD	Unpaid role Unpaid role Unpaid role
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
	Please place an "X" next to the following statement to indicate your agreement:		
	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	06/20/2024
Your Name:	Michelle M. Mielke
Manuscript Title:	Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
Manuscript Number (if known):	ADJ-D-24-00706

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	[⊠] None	Click the tab key to add additional rows.
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	None NIH: RF1 AG69052; RF1 AG077386; R01AG079397, U19 AG078109, U24 AG082930 DOD: W81XWH2110490 Alzheimer's Association Davos Alzheimer's Collaborative	To my institution

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None Non	
4	Consulting fees	Biogen, Eisai, Lilly, Merck, Roche, Siemens Healthineers, Novo Nordisk	Money paid to me
5	Dayment or	□ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Roche, Novo Nordisk	Money paid to me
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in	[□] None	

_		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid	Alzheimer's Drug Discovery Foundation	Money paid to me for grant review
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

3 12/13/2021 ICMJE Disclosure Form

Date:	6/23/2024
Your Name:	Daryl Rhys Jones
Manuscript Title:	[Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	[⊠] None	Click the tab key to add additional rows.
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None I own stock options with AbbVie and Eisai who both have interest in Alzheimer's disease	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	6/20/2024
Your Name:	John Dwyer
Manuscript Title:	[Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	[⊠] None	Click the tab key to add additional rows.
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	□ None	
		C2N, Quanterix, Fujirebio, Retispec	Paid licensing fees to participate in GAP's BH1 biomarker study
		Eli Lilly & Company, Biogen, Merck, Abbvie,	Paid licensing fees to participate in GAP's BH1 biomarker study
			Paid licensing fees to participate in GAP's BH1 biomarker study

ľ		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	President and Board Member of the Global Alzheimer's Foundation Board Member of Us Against Alzheimer's Board Member of Voices of Alzheimer's	Full-time Officer of the Foundation No Compensation No Compensation

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	-	t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:			6/19/2024		
Your Name:					
Manuscript Title:			Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease		
Mar	nuscript Number (if k	nown)	Click or tap here to enter text.		
content of your manuscript. "Relaffected by the content of the ma		pt. "R of the n	e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be unuscript. Disclosure represents a commitment to transparency and does not necessarily about whether to list a relationship/activity/interest, it is preferable that you do so.		
epid	•	nsion, y		example, if your manuscript pertains to the acturers of antihypertensive medication, even if	
	em #1 below, report ane for disclosure is the		· · · · · · · · · · · · · · · · · · ·	ithout time limit. For all other items, the time	
			all entities with whom you have this nship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
	All support for the present manuscript (e.g., funding, provision of study materials,	[□]	None	Consulting fees in partnership with Guidehouse	
	medical writing, article processing charges, etc.) No time limit for this item.			Click the tab key to add additional rows.	
	article processing charges, etc.) No time limit for		Time frame: past 36 month		
	article processing charges, etc.) No time limit for		Time frame: past 36 month		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	6/18/2024	
Your Name:	Emily Scholler	
Manuscript Title:	Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease	
Manuscript Number (if known):	[Click or tap here to enter text.]	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Time frame: past 36 month	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	None None	

1 12/13/2021 ICMJE Disclosure Form

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

3 12/13/2021 ICMJE Disclosure Form

Date:	6/18/2024
Your Name:	Fabricio Ferreira de Oliveira
Manuscript Title:	Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
Manuscript Number (if known):	ADJ-D-24-00706

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial planning of the work		
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from	None Time frame: past 36 months	Click the tab key to add additional rows.	
	any entity (if not indicated in item #1 above).	FAPESP – The State of São Paulo Research Foundation	grant #2015/10109-5	
3	Royalties or licenses	None None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	Gerson Lehrman Group Atheneum Partners Guidepoint Lionbridge	Payments made to me. Payments made to me. Payments made to me. Payments made to me.
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	Alzheimer's Association International Conference – AAIC>23 (Amsterdam)	The Alzheimer's Association sponsored the conference registration and the airfare.
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	American Academy of Neurology Global Strategies Subcommittee Awards Committee of the International Parkinson and Movement Society European Science Foundation Committee of Experts	Unpaid. Unpaid. Payments made to me.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Executive Committee Member, ISTAART Biofluid Based Biomarkers Professional Interest Area (Alzheimer's Association) Executive Committee Member, ISTAART Neuropsychiatric Syndromes Professional Interest Area (Alzheimer's Association)	Unpaid. Unpaid.
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs,		
	medical writing, gifts or other		
	services		
13	Other financial or non-financial	□ None	
	interests	Associate Editor, Clinical Neurology & Neurosurgery (Elsevier)	Payments made to me.
		Associate Editor, Journal of Alzheimer's Disease – JAD (IOS Press)	Unpaid.
		Associate Editor, Frontiers in Neuroscience (Frontiers Media)	Unpaid.
		Academic Editor, Medicine® (Wolters Kluwer Health)	Unpaid.
		Editorial Board Member, Neurology® (American Academy of Neurology)	Unpaid.
		Editorial Board Member, Neurology Letters (Iran University of Medical Sciences)	Unpaid.
		Grant Reviewer, University of Ljubljana (Slovenia)	Payments made to me.
		Grant Reviewer, Institut Pasteur (France)	Unpaid.
		Grant Reviewer, Ministry of Health (Brazil) Grant Reviewer, The State of São Paulo Research	Unpaid. Unpaid.
		Foundation – FAPESP (Brazil)	Oripaid.
		Grant Reviewer, The State of Rio Grande do Sul	Unpaid.
		Research Foundation – FAPERGS (Brazil) Grant Reviewer, The State of Tocantins Research	Unnaid
		Foundation – FAPT (Brazil)	Unpaid.
Plea	Please place an "X" next to the following statement to indicate your agreement:		
	I certify that I have	answered every question and have not altered the wo	ording of any of the questions on this form.

Date:	6/19/2024
Your Name:	Oskar Hansson
Manuscript Title:	[Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
Manuscript Number (if known):	NA

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	g of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	[⊠] None Time frame: past 36 mont	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	[□] None	
		AC Immune BioArctic Biogen Bristol Meyer Squibb	me me me me
		C2N Diagnostics Eisai Eli Lilly Fujirebio	institute me me me
		Merck Novartis Novo Nordisk Roche Sanofi Siemens	me me me me me me me me me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	None None □	
6	educational events Payment for	[⊠] None	
	expert testimony		
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		
[oxtimes]	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	6/24/2024
Your Name:	Drew Holzapfel
Manuscript Title:	Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		e all entities with whom you have this ionship or indicate none (add rows as ed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
2		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

1 12/13/2021 ICMJE Disclosure Form

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None Founding Executive Director of CEOi, which supporte	ed the formation of the Workgroup.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	[⊠] None	
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement: [I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	6/20/2024
Your Name:	Joel B. Braunstein
Manuscript Title:	[Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	[⊠] None	Click the tab key to add additional rows.
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	Dr. Braunstein is an employee and shareholder of C2N Diagnostics	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	Dr. Braunstein is an employee and shareholder of C2N Diagnostics	
Plea [⊠]	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	6/18/2024	
Your Name:	Katherine Ann Partrick	
Manuscript Title: [Considerations for widespread implementation of blood-based biomarkers of Alzheim disease		
Manuscript Number (if known):	[Click or tap here to enter text.]	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Payment received from Global CEO Initiative on Alzheimer's Disease for medical writing.	Click the tab key to add additional rows.
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	None None	

1 12/13/2021 ICMJE Disclosure Form

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None □	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None Payment received from Global CEO Initiative on Alzheimer's Disease for medical writing.	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	[⊠] None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None		
13	Other financial or non-financial interests	[⊠] None		
Plea	Please place an "X" next to the following statement to indicate your agreement: [I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

ICMJE DISCLOSURE FORM				
Date:	6/18/2024			
Your Name:	ARA S. KHACHATURIAN			
Manuscript Title:	Considerations for widespread implementa disease	[Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease		
Manuscript Number (if k	nown): [Click or tap here to enter text.]			
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.				
	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Prevent Alzheimer's Disease 20/20 Brain Watch Coalition	Click the tab key to add additional rows.
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	☑ None	
3	Royalties or licenses	None None □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if particular part	yments were
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Image: square of the property of the propert	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Prevent Alzheimer's Disease 20/20 Brain Watch Coalition	

ľ		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments we made to you or to your institution)		
11	Stock or stock options	[⊠] None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None		
13	Other financial or non-financial interests	Editor-in-Chief, Journal of Aging Research and Lifestyle Editor-in-Chief, Vitality, Medicine & Engineering Chair, Scientific Advisory Board, International Neurodegenerative Research Center		
Plea [⊠]	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

3 12/13/2021 ICMJE Disclosure Form

Date:			6/19/2024	
Your Name:			Marwan Noel Sabbagh, MD	
Manuscript Title:			Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease	
Ma	nuscript Number (if k	(nown):	Click or tap here to enter text.	
content of your manuscript. "Rela affected by the content of the man				
The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.				
	tem #1 below, report me for disclosure is th		· · · · · · · · · · · · · · · · · · ·	ithout time limit. For all other items, the time
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	⊠ No	one	Click the tab key to add additional rows.
			Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	PI: R01/ SABBAG 09/01/: A Phase Safety, in Patie Alzhein GC-201 SABBAG 01/01/:	AG059008 GH, MARWAN (PI) 18-05/31/24 e I Clinical Trial for the Assessment of Tolerability, and Efficacy of Lenalidomide ents with Mild Cognitive Impairment Due to ner's Disease 3717 GH, MARWAN (PI) 23-12/31/27 ment of Lenalidomide for Alzheimer's	

LBDA1811MS

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		SABBAGH, MARWAN (PI) 05/15/17-04/30/23 Research Center of Excelence (RCOE) designation R01 AG073212 SABBAGH, MARWAN (PI) WILSON, JEFFREY (MPI) DECOURT, BORIS (MPI) Repurposing Siponimod for Alzheimer's Disease 4/1/21- 3/30/26 Site PI TRC-DS 1R61AG066543-01 (R61AG066543) Site PI:ADRC- 1P30AG072980-01 Site PI: ADNI-U19AG024904	
3	Royalties or licenses	None	
4	Consulting fees	Roche-Genentech, Eisai, Lily, Synaptogenix, Neuro Therapia, Signant Health, Novo Nordisk, Prothena, KeiferRx, Anavex, Cognito Therapeutics, GSK, Abbvie	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
8	Patents planned, issued or pending	None		
9	Participation on a Data Safety Monitoring Board or Advisory Board	None		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None EIP Pharma/CervoMed		
11	Stock or stock options	NeuroTau, Optimal Cognitive Health Company, Method Health, Versanum, Athira, TransDermix, Seq BioMarque, NeuroReserve, Lighthouse Pharmaceuticals, Alzheon, Reservoir Neuroscience		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
13	Other financial or non-financial interests	None ■		
Plea	Please place an "X" next to the following statement to indicate your agreement:			
\boxtimes	I certify that I have	answered every question and have not altered the wo	rding of any of the questions on this form.	

6/19/24

Date:			6/19/2024	
Your Name:		•	Soeren Mattke	
Manuscript Title:			Considerations for widespread implementa disease	tion of blood-based biomarkers of Alzheimer's
Mar	nuscript Number (if kr	nown):	Click or tap here to enter text.	
confaffe indicate that	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.		ot-for-profit third parties whose interests may be not to transparency and does not necessarily /interest, it is preferable that you do so. example, if your manuscript pertains to the acturers of antihypertensive medication, even if	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	[⊠] No	one	Click the tab key to add additional rows.
			Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).		one , C2N, Eisai, Roche	Research contracts to USC
3	Royalties or licenses	⊠ No	one	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None Biogen, C2N, Eisai, Roche/Genentech, Novo Nordisk	Personal consulting fees
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None Roche, Novartis, Novo Nordisk, Eisai, Eli Lilly	Honoraria for educational events
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[D] None	Travel to AAIC 2023
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None Roche	Advisory Boards
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Senscio Systems	Board of Directors

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	AiCure Technologies, Alzpath and Boston Millennia Partners	Scientific advisory board
Plea [⊠]	•	t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:	6/24/2024
Your Name:	Michael W. Weiner
Manuscript Title:	[Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	g of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None NIH Grant: 5R01AG058676-02 NIH Grant: 2 U19 AG024904.16	Payments were made to my institution. Payments were made to my institution. Click the tab key to add additional rows.
		Time frame: past 36 mont	hc
2	Grants or contracts from	□ None	
	any entity (if not indicated in item #1 above).	NIH Grant: 5U2CAG060426-04 NIH Grant: 1RF1AG059009-01 NIH Grant: R33 AG062867 NIH Grant: 1R01NS119651-01 NIH Grant: RF1AG062196 NIH Grant: R56AG075744-01A1 Additional support from Department of Defense (DOD) Additional support from: California Department of Public Health (CDPH) Additional support from: Siemens Additional support from: Biogen Additional support from: Hillblom Foundation	Payments were made to my institution. Payments were made to my institution. Payments were made to my institution. Payments were made to my institution. Payments were made to my institution. Payments were made to my institution.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Additional support from: Alzheimer's Association Additional support from: Johnson & Johnson Additional support from: Kevin and Connie Shanahan Additional support from: GE Additional support from: VUmc Additional support from: Australian Catholic University (HBI-BHR) Additional support from: The Stroke Foundation	Payments were made to my institution. Payments were made to my institution. Payments were made to my institution. Payments were made to my institution. Payments were made to my institution. Payments were made to my institution. Payments were made to my institution.
3	Royalties or licenses	Additional support from: Veterans Administration None	Payments were made to my institution.
4	Consulting fees	□ None	
		Boxer Capital Cerecin Clario/BioClinica Dementia Society of Japan Eisai Guidepoint Health and Wellness Partners Indiana U. LCN Consulting Merck Sharp & Dohme Corp. Duke U. Prova Education T3D Therapeutics University of Southern CA (USC) WebMD MEDA Corp.	Payment was made directly to me.
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	China Association for Alzheimer's Disease (CAAD) Taipei Medical University Cleveland Clinic AD/PD Congress Foundation of Learning; Health Society (Japan) INSPIRE Project; U. Toulouse Japan Society for Dementia Research Korean Dementia Society Merck Sharp & Dohme Corp., National Center for Geriatrics and Gerontology (NCGG; Japan University of Southern California (USC)	Payment was made directly to me.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
6	Payment for expert testimony	Image: square of the square o	
7	Support for attending	□ None	
	meetings and/or travel	AD/PD Congress	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		Cleveland Clinic	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		CTAD Congress	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		Foundation of Learning; Health Society (Japan)	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		INSPIRE Project; U. Toulouse Japan Society for Dementia Research	Payment was made either directly to the travel accommodations provider, or reimbursed to me. Payment was made either directly to the travel
		Korean Dementia Society	accommodations provider, or reimbursed to me. Payment was made either directly to the travel
		Merck Sharp & Dohme Corp.,	accommodations provider, or reimbursed to me. Payment was made either directly to the travel
		National Center for Geriatrics and Gerontology (NCGG; Japan	accommodations provider, or reimbursed to me. Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		University of Southern California (USC)	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
8	Patents planned, issued or		
	pending		
9	Participation on a Data Safety	None	
	Monitoring Board or Advisory Board	ADNI Scientific Advisory Board UCSF Committee for Human Research	Leadership Committee Member
10	Leadership or fiduciary role in	□ None	
	other board, society,	UCSF Inclusion Diversity Equity & Awareness Committee	Leadership
	committee or advocacy group, paid or unpaid	Diversity Task Force of the Alzheimer's Disease Neuroimaging Initiative (ADNI)	Leadership
	paid of unipaid		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	□ None	
		Alzeca	Stock options held.
		Alzheon, Inc.	Stock options held.
		ALZPath	Stock options held.
		Anven	Stock options held.
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea [⊠]		t to the following statement to indicate your agreeme answered every question and have not altered the wo	

		ICMJE DISCLOSURE FOI	RM
Da	te:	6/24/2024	
Yo	ur Name:	Mark Monane	
Ma	nuscript Title:	Considerations for widespread implementate disease	cion of blood-based biomarkers of Alzheimer's
Ma	ınuscript Number (if kn	oown): Click or top here to enter text.	
cor aff ind The ep tha	ntent of your manuscrip ected by the content of licate a bias. If you are e author's relationships idemiology of hyperten at medication is not me	ency, we ask you to disclose all relationships/activities of the manuscript. Disclosure represents a commitment in doubt about whether to list a relationship/activity/s/activities/interests should be defined broadly. For elsion, you should declare all relationships with manufantioned in the manuscript. Ill support for the work reported in this manuscript with past 36 months.	t-for-profit third parties whose interests may be not to transparency and does not necessarily (interest, it is preferable that you do so. xample, if your manuscript pertains to the acturers of antihypertensive medication, even if
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame; Since the initial planning o	of the work
1	All support for the	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame; past 36 month	ds
2	Grants or contracts from any entity (if not indicated in item #1 above).	None None	
3	Royalties or licenses	None .	

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees		None	
	,	C2N	Diagnostics, LLC	Paid to me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events		None	
6	Payment for expert testimony	×	None	
7	Support for attending meetings and/or	C2N Diagnostics, LLC Paid to me		
	travel			
8	Patents planned, issued or pending	8	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board		None	_
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	×	None	

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	C2N	None Diagnostics, LLC	Paid to me
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X	None	
13	Other financial or non-financial interests		None	
Plea			e following statement to indicate your agreeme ered every question and have not altered the wo	

Date:		8/2	8/26/2021		
You	r Name:	Jam	James F Murray		
Manuscript Title:			nsiderations for widespread implemen ease	tation of blood-based biomarkers of Alzheimer's	
Ma	nuscript Number (if k	nown): Clic	k or tap here to enter text.		
con affe indi The epic tha	tent of your manuscricted by the content of cate a bias. If you are author's relationship demiology of hyperters medication is not me	pt. "Related" of the manuscre of in doubt abo s/activities/in nsion, you sho entioned in the	means any relation with for-profit or ript. Disclosure represents a commitm ut whether to list a relationship/activiterests should be defined broadly. Fould declare all relationships with man e manuscript.	ries/interests listed below that are related to the not-for-profit third parties whose interests may be ent to transparency and does not necessarily cy/interest, it is preferable that you do so. The example, if your manuscript pertains to the ufacturers of antihypertensive medication, even if without time limit. For all other items, the time	
			ities with whom you have this or indicate none (add rows as needed	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planni	ng of the work	
1	All support for the present	□ None			
1			imer's Collaborative – System	Time for meetings was supported as part of my regular duties	
1	present manuscript (e.g., funding, provision of study materials,	Davos Alzhei	imer's Collaborative – System	Time for meetings was supported as part of my regular duties	
1	present manuscript (e.g., funding, provision	Davos Alzhei	imer's Collaborative – System	Time for meetings was supported as part of my	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Davos Alzhei	imer's Collaborative – System	Time for meetings was supported as part of my regular duties Click the tab key to add additional rows.	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Davos Alzhei	imer's Collaborative – System ss	Time for meetings was supported as part of my regular duties Click the tab key to add additional rows.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None Davos Alzheimer's Collaborative — System Preparedness	Time for meetings was supported as part of my regular duties
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	Davos Alzheimer's Collaborative – System Preparedness	Time for meetings was supported as part of my regular duties
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	Eli Lilly and Company, Inc	Retired Stock Holder
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea [⊠]	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	25 June 2024
Your Name:	Richard Batrla
Manuscript Title:	Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	<u>x</u>	None	Click the tab key to add additional rows.
	this item.			
			Time frame: past 36 month	ns .
2	Grants or contracts from any entity (if not	<u>x</u>	None	
	indicated in item #1 above).			
	HI abovej.			
3	Royalties or licenses	X	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	x None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None Employment by Eisai - Pharmaceutical company manufacturing Lecanemab	
6	Payment for expert testimony	χ N one	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	x None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	x None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	x None	
13	Other financial or non-financial interests	x None	

Please place an "X" next to the following statement to indicate your agreement:

x I certify that I have answered every question and have not altered the wording of any of the questions on this form.

	ICMJE DISCLOSURE FORM				
Da	Date: 6/20/2024				
You	ur Name:	Allyson C. Rosen			
Ma	Considerations for widespread implementation of blood-based biomarkers of Alzheimer's <pre>disease</pre>				
Ma	nuscript Number (if I	known): Click or tap here to enter text.			
cor affind The epi tha	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be diffected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if hat medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time rame for disclosure is the past 36 months.				
		· ·	ons/Comments (e.g., if payments were ou or to your institution)		
		Time frame: Since the initial planning of the work			
1	All support for the present	[⊠] None			

manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months Grants or 2 None contracts from any entity (if not Mental Illness Research Education and Clinical indicated in item Center (MIRECC) #1 above). Royalties or **⊠** None 3 licenses

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments made to you or to your institution)	were
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Advisory Group on Risk Evidence for Dementia	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:			6/24/2024	
You	r Name:		Eli Shobin	
Manuscript Title:			[Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease	
Mar	nuscript Number (if k	nown):	Click or tap here to enter text.	
content of your manuscript. "Rela affected by the content of the mai indicate a bias. If you are in doubt		ipt. "Rel of the ma e in doub		/interest, it is preferable that you do so.
-	lemiology of hyperter medication is not me	-		acturers of antihypertensive medication, even if
	em #1 below, report ne for disclosure is the			ithout time limit. For all other items, the time
			Il entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials	[□] N	lone	Employer
1	present manuscript (e.g.,		lone	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for		lone	Employer Click the tab key to add additional rows.
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Biogen	lone	Employer Click the tab key to add additional rows.
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item	Biogen	Time frame: past 36 month	Employer Click the tab key to add additional rows.
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above). Royalties or	Biogen	Time frame: past 36 month	Employer Click the tab key to add additional rows.
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above). Royalties or	Biogen	Time frame: past 36 month	Employer Click the tab key to add additional rows.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[□] None Biogen	Employer
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Alzheimer's Drug Discovery Foundation	Head of the Diagnostics Accelerator

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None Biogen Eli Lilly Abbvie	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea [⊠]	•	t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:	6/20/2024
Your Name:	Pei-Jung Lin
Manuscript Title:	[Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
Manuscript Number (if known):	[Click or tap here to enter text.]

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	[⊠] None	Click the tab key to add additional rows.
		Time frame: past 36 month	ıs
2	Grants or contracts from any entity (if not indicated in item #1 above).	NIA Biogen Eisai Genentech/Roche Lilly	Research funds made to Tufts Medical Center
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None Lilly	Payments made to me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	None None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

	ICMJE DISCLOSURE FO	RM	
Date:	Date: 6/19/2024		
Your Name:	Suzanne E. Schindler		
Manuscript Title:	Considerations for widespread implemental disease	[Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease	
Manuscript Number (if kı	nown): Click or tap here to enter text.		
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.		ot-for-profit third parties whose interests may be not to transparency and does not necessarily /interest, it is preferable that you do so. example, if your manuscript pertains to the acturers of antihypertensive medication, even if ithout time limit. For all other items, the time	
	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
	Time frame: Since the initial planning	of the work	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	[⊠] None	Click the tab key to add additional rows.
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	None Barnes-Jewish Hospital Foundation National Institute on Aging grant R01AG070941 (SE Schindler)	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	[□] None	
		Eisai	Consulting fees for advisory boards on blood biomarkers and biomarker education for providers
		Novo Nordisk	Consulting fees for advisory board on blood biomarkers and biomarker education for providers
5	Payment or	□ None	
3	honoraria for lectures,		
	presentations, speakers bureaus, manuscript writing or	Eli Lilly University of Wisconsin, St. Luke's Hospital, Houston Methodist Medical Center, Weill Cornell, University of Massachusetts, Zucker School of Medicine, Medscape, (ATRI)/University of Southern California	Honoraria for presenting lecture Honoraria for presenting lectures
	educational events	University of Washington	Honoraria for serving on the Alzheimer Disease Center Clinical Task Force
		University of Indiana	Honoraria for serving on the National Centralized Repository for Alzheimer's Disease biospecimen review committee
6	Payment for expert testimony	None	
7	Support for attending	[□] None	
	meetings and/or travel	National Institute on Aging grant R01AG070941 (SE Schindler)	Travel support is included in NIH grant
		Alzheimer's Association	Travel support for 2023 AAIC and 2023 Research Roundtable
		US Against Alzheimer's	Travel support for Lausanne X
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety	[□] N one	
	Monitoring Board or Advisory Board	World Health Organization	Participating in a committee advising the WHO on preferred product characteristics for fluid biomarkers of Alzheimer disease.
		University of Washington	Served on the Alzheimer Disease Center Clinical Task Force that is revising the data collection set

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		University of Indiana University of Michigan	used by all ADRCs; attended meetings every 2 weeks and did additional research and writing. Reviewing sample requests for the National Centralized Repository for Alzheimer's Disease biospecimen review committee. Member of the External Advisory Committee reviewing the Michigan ADRC and providing
			recommendations.
Leadership or fiduciary role in other board,		☐ None Greater Missouri Chapter of the Alzheimer's	Board member working to support local efforts to
	society, committee or	Association	raise funds for the Alzheimer's Association and advise them on research and support.
	advocacy group, paid or unpaid	Global CEO initiative workgroup on Blood-Based Biomarkers	Co-leader of workgroup tasked with developing performance standards for blood-based biomarkers; attended weekly meetings for ~6 months and worked on writing paper.
		Advisory Group on Risk Evaluation Education for Dementia	Participated in monthly calls discussing the ethical and legal implications of research on dementia that could allow for prediction of individual risk.
		Foundation for the National Institutes of Health Biomarkers Consortium	Project team member participating in planning head-to-head studies of blood-based biomarker assays.
l 1	Stock or stock options	[⊠] None	
L2	Receipt of equipment,	[□] None	
	materials, drugs, medical writing, gifts or other services	C2N Diagnostics	Plasma Ab42/Ab40 data was provided to Washington University by C2N Diagnostics at no cost. No payments/research funding was provided by C2N Diagnostics. No gifts/financial incentives of any kind have been provided to Dr. Schindler by C2N Diagnostics.
	- 1 6		
L3	Other financial or non-financial interests		

Name all entities with whom you have this		
relationship or indicate none (add rows as needed)		

Specifications/Comments (e.g., if payments were made to you or to your institution)

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	6/18/2024
Your Name:	Jamie Tyrone
Manuscript Title:	[Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	[⊠] None	Click the tab key to add additional rows.
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	□ None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	[⊠] None
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Advisory Group on Risk Evidence for Dementia Co-Chairperson for Stakeholder Sub-committee

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

	iewse siscessone i suur		
Date:	Pate: 6/20/2024		
Your Name:	Lawren VandeVrede		
Manuscript Title:	Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease		
Manuscript Number (if known):	Click or tap here to enter text.		
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NIH K23AG073514 Alzheimer's Association Shenandoah Foundation	Click the tab key to add additional rows.
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	6/24/2024	
Your Name:	George Vradenburg	
Manuscript Title:	Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease	
Manuscript Number (if known):	Click or tap here to enter text.	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial plan	ning of the work
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	[⊠] None Time frame: past 36 m	Click the tab key to add additional rows.
Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	None Non	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☐ None Convener of CEOi, which supported the formation	of the Workgroup.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	[⊠] None	
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	6/25/2024
Your Name:	Joan Weiss, PhD, RN, CRNP, FAAN
Manuscript Title:	[Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:		6/19/2024			
Your Name:		Deanna R Willis MD MBA			
Manuscript Title:		Considerations for widespread implementa disease	Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease		
Ma	nuscript Number (if know	Click or tap here to enter text.			
cor affe	itent of your manuscript. ' ected by the content of the	Related" means any relation with for-profit or no manuscript. Disclosure represents a commitme	e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so.		
epi		you should declare all relationships with manuf	es/interests should be defined broadly. For example, if your manuscript pertains to the u should declare all relationships with manufacturers of antihypertensive medication, even if in the manuscript.		
	tem #1 below, report all su me for disclosure is the pas	pport for the work reported in this manuscript w t 36 months.	rithout time limit. For all other items, the time		
I BERTHANNER BERTHANNE BERTHANNER BERTHANNER BERTHANNER BERTHANNER BERTHANNER BERTHANNER BERTHANNER BERTHANNER		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
2 - 3.7 7.3 8.4 8.4 8.4	· 图 · 图 · 图 · 图 · 图 · 图 · 图 · 图 · 图 · 图	Time frame: Since the initial planning	of the work		
150					
1	All support for the present	None			
1	present	and the conference of the second of the seco	Payments to Indiana University for services of Being Principal Investigator on a research study		
1	present manuscript (e.g., funding, provision of study materials,	None	Payments to Indiana University for services of		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing	None	Payments to Indiana University for services of Being Principal Investigator on a research study They funded that was on early detection in primary care.		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	None	Payments to Indiana University for services of Being Principal Investigator on a research study They funded that was on early detection in primary care.		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	None os Alzheimer's Collaborative	Payments to Indiana University for services of Being Principal Investigator on a research study They funded that was on early detection in primary care. That work is NOT specifically referenced in this manuscript		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Payments to Indiana University for services of Being Principal Investigator on a research study They funded that was on early detection in primary care. That work is NOT specifically referenced in this manuscript		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None os Alzheimer's Collaborative Time frame: past 36 month	Payments to Indiana University for services of Being Principal Investigator on a research study They funded that was on early detection in primary care. That work is NOT specifically referenced in this manuscript		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None os Alzheimer's Collaborative Time frame: past 36 month	Payments to Indiana University for services of Being Principal Investigator on a research study They funded that was on early detection in primary care. That work is NOT specifically referenced in this manuscript		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None os Alzheimer's Collaborative Time frame: past 36 month	Payments to Indiana University for services of Being Principal Investigator on a research study They funded that was on early detection in primary care. That work is NOT specifically referenced in this manuscript		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Os Alzheimer's Collaborative Time frame: past 36 month None	Payments to Indiana University for services of Being Principal Investigator on a research study They funded that was on early detection in primary care. That work is NOT specifically referenced in this manuscript		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None os Alzheimer's Collaborative Time frame: past 36 month	Payments to Indiana University for services of Being Principal Investigator on a research study They funded that was on early detection in primary care. That work is NOT specifically referenced in this manuscript		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	None Os Alzheimer's Collaborative Time frame: past 36 month None	Payments to Indiana University for services of Being Principal Investigator on a research study They funded that was on early detection in primary care. That work is NOT specifically referenced in this manuscript		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	None Os Alzheimer's Collaborative Time frame: past 36 month None	Payments to Indiana University for services of Being Principal Investigator on a research study They funded that was on early detection in primary care. That work is NOT specifically referenced in this manuscript		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None :	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	Davos Alzheimer's Collaborative	As noted under #1 to attend Davos Collaborative meetings
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None Voices of Alzheimer's	Assisting as unpaid advisor to help advocacy efforts through communication with primary care physicians.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
transfer for a	Stock or stock	□ None	
		Resonea	Stock owner in company using FDA cleared mobile app to detect sleep apnea. Company no longer exists.
		Topera	Stock owner in company working to improve diagnosis and treatment of atrial fibrillation. Company sold to Abbott. No longer receiving payments from sale.
1	Receipt of equipment,	□ None	
	materials, drugs, medical writing, gifts or other	Linus Health	Provided in kind devices and software for Davos Alzheimer's Collaborative of Digital cognitive assessment device
	services	C2N Diagnostics	Provided in kind blood based biomarker testing for Davos Alzheimer's Collaborative (PrecivityAD)
	Other financial or non-financial	None	
Printed to the	interests		

12/13/2021

10/19/24 Deanna & Will's

Date:	6/18/2024
Your Name:	Yan Helen Hu
Manuscript Title:	[Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Time frame: past 36 month	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	None Non	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:		-	6/25/2024			
Your Name:		·-	Zul Merali			
Manuscript Title:		<u>-</u>	[Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease			
Manuscript Number (if known):		known):	Click or tap here to enter text.			
content of your manuscript. "Rela affected by the content of the mar			e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so.			
-			es/interests should be defined broadly. For example, if your manuscript pertains to the u should declare all relationships with manufacturers of antihypertensive medication, even if in the manuscript.			
In item #1 below, report all support frame for disclosure is the past 36 r				ithout time limit. For all other items, the time		
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		one	Click the tab key to add additional rows.		
	Time frame: past 36 months					
2	Grants or contracts from any entity (if not indicated in item #1 above).	Davos A	Alzheimer's Collaborative; me Leap			
3	Royalties or licenses	⊠ No	one			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None □	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	□ None Aga Khan University	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Founding Director, Brain and Mind Institute, Aga Khan University	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
11	Stock or stock options	[⊠] None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None			
13	Other financial or non-financial interests	[⊠] None			
Please place an "X" next to the following statement to indicate your agreement:					